Basilea gibt Erhalt des Orphan-Drug-Status von der US-amerikanischen FDA für Lisavanbulin für die Behandlung von malignen Gliomen bekannt

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling